RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Royalty Pharma plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$60.27−0.69 (-1.13%)

Close on Oct 19, 2026

Market cap: $33.56B
P/E (TTM): 34.2
Dividend yield: –

Royalty Pharma plc income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	2,378	2,264	2,355	2,237	2,289	2,122	1,814	1,795
Research & Development	452	2.00	52	177	200	26	83	393
General & Administrative	573	237	250	227	183	182	103	62
Total Costs & Expenses	819	971	862	1,930	859	527	-809	430
Operating Income	1,560	1,292	1,492	307	1,431	1,595	2,623	1,364
Interest Expense	308	226	187	188	166	157	269	280
Interest & Investment Income	34	47	72	78	–	–	–	–
Income from Equity Investments	29	30	29	-8.97	-19	44	-33	-7.02
Other Non-Operating Income	-235	38	208	-77	-190	107	-162	153
Asset Impairment Charges	–	0	0	616	0	65	0	0
Pretax Income	1,324	1,331	1,700	230	1,241	1,702	2,461	1,518
Income Tax Expense	0	0	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	1,324	1,331	1,700	230	1,241	1,702	2,461	1,518
Minority Interest in Earnings	553	472	565	187	621	727	113	140
Net Income	771	859	1,135	43	620	975	2,349	1,378
Net Income to Common	771	859	1,135	43	620	495	–	–
EPS (Basic)(per share)	1.79	1.92	2.54	0.10	1.49	1.32	–	–
EPS (Diluted)(per share)	1.78	1.91	2.53	0.10	1.49	1.32	–	–
Shares Outstanding (Basic, Weighted)(shares)	430	448	448	438	415	375	–	–
Shares Outstanding (Diluted, Weighted)(shares)	564	594	603	438	415	375	–	–
Dividend per Share(per share)	–	0.84	0.80	0.76	0.68	0.30	–	–
Provision for Credit Losses	26	-100	-22	-194	-13	156	-1,019	-57

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 59.6%
Net margin: 32.1%
Return on equity, FY2025: –

Financial strength

Current ratio: 2.80
Debt to equity: –
Debt to assets: 45.2%
Cash to current liabilities: 128.7%

Valuation

P/E ratio: 34.2
Price to sales: 13.24
Price to book: –
Dividend yield: –